Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism (STRATEGY-PE)

17 de mayo de 2026 actualizado por: Nanjing First Hospital, Nanjing Medical University

Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study

This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.

Descripción general del estudio

Descripción detallada

Background: Acute pulmonary embolism (PE) is a severe manifestation of venous thromboembolism (VTE). Intermediate-high risk PE accounts for 20-30% of all PE cases with significant mortality driven by right ventricular (RV) dysfunction. Current guidelines recommend anticoagulation for all, with thrombolysis or mechanical thrombectomy as rescue or alternative therapies. However, there is significant heterogeneity in real-world treatment selection and a lack of head-to-head comparative evidence among the three strategies in complex real-world populations.

Objective: To compare the 30-day and 90-day all-cause mortality and 48-hour RV/LV ratio improvement rate among three treatment strategies (Anticoagulation, Thrombolysis, Mechanical Thrombectomy) in patients with intermediate-high risk acute PE.

Design: This is a prospective, multicenter, non-randomized, pragmatic cohort study. Treatment allocation is based on routine clinical decision-making (natural allocation) without investigator intervention. Advanced statistical methods (Propensity Score Matching/Weighting, Instrumental Variable analysis) will be used to control for confounding factors.

Participants: 1,300 patients with confirmed acute intermediate-high risk PE (RV/LV ratio ≥0.9 and elevated cardiac biomarkers, hemodynamically stable). There are no age limits to reflect real-world diversity.

Interventions/Exposures:

  1. Anticoagulation (AC): Standard anticoagulant therapy (LMWH, DOAC, UFH, or Warfarin).
  2. Thrombolysis (TL): Systemic thrombolysis or Catheter-Directed Thrombolysis (CDT) using agents like Urokinase, Alteplase, etc.
  3. Mechanical Thrombectomy (MT): Mechanical removal of thrombus using FDA/NMPA approved devices (e.g., Indigo, FlowTriever, Acoscream), with or without adjunctive anticoagulation/thrombolysis.

Outcomes:

  • Primary: 30-day and 90-day all-cause mortality; 48-hour RV/LV ratio improvement rate (≥15% reduction).
  • Secondary: Clinical deterioration, major bleeding (ISTH/GUSTO/BARC), functional status (6MWT, NYHA, PVFS), quality of life (PEmb-QoL, EQ-5D-5L), PE recurrence, and healthcare resource utilization.

Follow-up: Patients will be followed at 48 hours, 7 days, 30 days, and 90 days.

Tipo de estudio

De observación

Inscripción (Estimado)

1300

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: he xu Dr, doctor
  • Número de teléfono: +86 153 6611 0045
  • Correo electrónico: kilogram@163.com

Ubicaciones de estudio

    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210006
        • Nanjing First Hospital
        • Contacto:
          • Interventional Vascular Department Director, doctor
          • Número de teléfono: +86-25-52271000
          • Correo electrónico: kilogram@163.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Patients diagnosed with intermediate-high risk acute pulmonary embolism admitted to participating tertiary hospitals with Pulmonary Embolism Response Teams (PERT).

Descripción

Inclusion Criteria:

  • Age unlimited (reflecting real-world population).
  • Symptom duration of acute PE ≤ 14 days.
  • Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.
  • Defined as Intermediate-High Risk PE meeting all of the following:
  • RV/LV ratio ≥ 0.9 (by CT or Echocardiography).
  • Elevated cardiac biomarkers (Troponin > 99th percentile or BNP > 100 pg/mL).
  • Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).
  • Able to provide informed consent and complete follow-up.

Exclusion Criteria:

  • Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.
  • Unable to obtain baseline or follow-up CTPA imaging.
  • (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Anticoagulation Cohort
Patients receiving standard anticoagulation therapy alone without thrombolysis or mechanical thrombectomy.
Low Molecular Weight Heparin (LMWH), Direct Oral Anticoagulants (DOAC), Unfractionated Heparin (UFH), or Warfarin according to guideline-standard regimens.
Otros nombres:
  • Heparin, Enoxaparin, Rivaroxaban, Apixaban, Dabigatran, Edoxaban, Warfarin
Thrombolysis Cohort
Patients receiving systemic thrombolysis or catheter-directed thrombolysis.
Any FDA/NMPA approved mechanical thrombectomy device (e.g., Indigo, FlowTriever, Acoscream) used for clot removal.
Otros nombres:
  • Indigo Aspiration System, FlowTriever, Acostream
Mechanical Thrombectomy Cohort
Patients undergoing mechanical thrombectomy procedures using percutaneous devices.
Urokinase, Pro-urokinase, Alteplase, or Tenecteplase administered systemically or via catheter.
Otros nombres:
  • tPA, rt-PA, Urokinase, Tenecteplase

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
All-Cause Mortality at 30 Days
Periodo de tiempo: 30 days
The percentage of participants who die from any cause within 30 days of enrollment.
30 days
All-Cause Mortality at 90 Days
Periodo de tiempo: 90 days
The percentage of participants who die from any cause within 90 days of enrollment.
90 days
Right Ventricular to Left Ventricular (RV/LV) Ratio Improvement Rate at 48 Hours
Periodo de tiempo: 48 hours ± 6 hours
The proportion of participants with a reduction in RV/LV ratio ≥15% from baseline measured by CTPA or Echocardiography.
48 hours ± 6 hours

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Major Bleeding Events
Periodo de tiempo: 48 hours, 7 days, 30 days, 90 days
Incidence of major bleeding defined by ISTH, GUSTO, or BARC criteria (including intracranial hemorrhage).
48 hours, 7 days, 30 days, 90 days
Clinical Deterioration
Periodo de tiempo: 48 hours, 7 days
Composite of hemodynamic instability, need for rescue therapy (escalation to thrombolysis/MT/ECMO), intubation, or PE-related death.
48 hours, 7 days
6-Minute Walk Test (6MWT) Distance
Periodo de tiempo: 30 days, 90 days
Change in walking distance from baseline (estimated) to follow-up. Minimal Clinically Important Difference (MCID) ≥30 meters.
30 days, 90 days
Post-VTE Functional Status (PVFS) Score
Periodo de tiempo: 30 days, 90 days
Assessment of functional limitation due to VTE (Scale 0-5).
30 days, 90 days
Quality of Life (PEmb-QoL)
Periodo de tiempo: 90 days

The questionnaire consists of 9 questions containing 40 items, which are organized into 6 domains:

Frequency of Complaints (FC): Assesses the frequency of respiratory and general symptoms (e.g., dyspnea, chest pain).

Daily Activity Limitations (AL): Measures limitations in performing activities of daily living (ADL).

Work-related Problems (WP): Evaluates difficulties in performing work or school duties.

Social Limitations (SL): Assesses restrictions on social activities. Intensity of Complaints (IC): Measures the severity of pain and breathlessness.

Emotional Complaints (EC): Captures anxiety, frustration, and fear related to the disease.

90 days
Symptomatic PE Recurrence
Periodo de tiempo: 90 days
Confirmed recurrent PE via CTPA or V/Q scan.
90 days
ICU Length of Stay
Periodo de tiempo: From ICU admission to ICU discharge, assessed up to 30 days
Duration of intensive care unit stay during the index hospitalization
From ICU admission to ICU discharge, assessed up to 30 days
Total Hospital Length of Stay
Periodo de tiempo: From hospital admission to hospital discharge, assessed up to 90 days
Duration of index hospitalization from emergency department admission to hospital discharge
From hospital admission to hospital discharge, assessed up to 90 days
Total Medical Costs
Periodo de tiempo: Through 90 days
Direct medical costs incurred during index hospitalization and within 90 days of enrollment, including medications, procedures, and hospitalization
Through 90 days

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Biomarker Improvement (Troponin, BNP, D-Dimer)
Periodo de tiempo: 48 hours, 7 days
Percentage reduction in cardiac biomarkers and D-Dimer levels.
48 hours, 7 days
Daily Step Count
Periodo de tiempo: Continuous monitoring through 90 days
Average daily step count measured by smart band (e.g., Xiaomi/Huawei/Apple Watch) during the 90-day follow-up period. Assessed as a continuous variable (steps/day) and correlated with 6-Minute Walk Test distance and Post-VTE Functional Status score.
Continuous monitoring through 90 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de junio de 2026

Finalización primaria (Estimado)

1 de marzo de 2028

Finalización del estudio (Estimado)

31 de diciembre de 2029

Fechas de registro del estudio

Enviado por primera vez

24 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de mayo de 2026

Publicado por primera vez (Actual)

22 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de mayo de 2026

Última verificación

1 de julio de 2025

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data (IPD) and data dictionaries will be made available to researchers upon reasonable request after the publication of the primary results.

Marco de tiempo para compartir IPD

Starting 6 months after publication of the primary results, available for 5 years.

Criterios de acceso compartido de IPD

Data will be shared with researchers who provide a methodologically sound proposal and whose use of data is for legitimate research purposes. Requests should be directed to the Principal Investigator.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir